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Summary
Background The NEAT/BR9601 trial showed beneﬁ t for addition of anthracyclines to cyclophosphamide, methotrexate, 
and ﬂ uorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive 
biomarkers of anthracycline beneﬁ t including HER2 and TOP2A. 
Methods 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 
and TOP2A ampliﬁ cation and deletion, HER1–3 and Ki67 expression, and duplication of chromosome 17 centromere 
enumeration probe (Ch17CEP). Log-rank analyses identiﬁ ed factors aﬀ ecting relapse-free and overall survival, and 
regression models tested independent prognostic eﬀ ect of markers, with adjustment for known prognostic factors 
(age, nodal status, oestrogen-receptor status, grade, and tumour size). The predictive value of markers was tested by 
treatment interactions for relapse-free and overall survival.
Findings 1762 patients were analysed. 21% of tumours (n=367) were HER2 ampliﬁ ed, 10% were TOP2A ampliﬁ ed 
(n=169), 11% showed TOP2A deleted (n=191), 23% showed Ch17CEP duplication (n=406), and 61% had high (>13·0%) 
Ki67 (n=1136). In univariate analyses, only HER2 ampliﬁ cation and TOP2A deletion were signiﬁ cant prognostic 
factors for relapse-free (hazard ratio [HR] 1·59, 95% CI 1·32–1·92, p<0·0001; and 1·52, 1·20–1·92, p=0·0006, 
respectively) and overall survival (1·79, 1·47–2·19, p<0·0001; and 1·62, 1·26–2·08, p=0·0002 respectively). We 
detected no signiﬁ cant interaction with anthracycline beneﬁ t for Ki67, HER2, HER1–3, or TOP2A. By contrast, in 
multivariate analyses, Ch17CEP duplication was associated with signiﬁ cant improvements in both relapse-free 
(HR 0·92, 95% CI 0·72–1·18 for tumours with normal Ch17CEP vs 0·52, 0·34–0·81 for tumours with abnormal 
Ch17CEP; p for interaction=0·004) and overall survival (0·94, 0·72–1·24 vs 0·57, 0·36–0·92; p for interaction=0·02) 
with anthracycline use.
Interpretation In women with early breast cancer receiving adjuvant chemotherapy, the most powerful predictor of 
beneﬁ t from anthracyclines is Ch17CEP duplication. In view of the location of HER2/TOP2A on chromosome 17, 
Ch17CEP duplication might explain the inconsistencies in previous studies of factors predicting beneﬁ t from 
anthracyclines.
Funding Cancer Research UK and the Scottish Breast Cancer Clinical Trials Group.
Introduction
Breast cancer is recognised as a disease of substantial 
molecular diversity.1 The search for predictive biomarkers 
that can be applied to guide selection of appropriate 
therapies for diﬀ erent patient subgroups is intensifying. 
The HER2 oncogene is frequently cited as a biomarker of 
sensitivity or resistance to endocrine treatment and 
chemotherapy.2,3 The HER2 oncogene is ampliﬁ ed or 
overexpressed in about 25% of early breast cancer cases for 
which adjuvant anthracycline use is considered in the UK.4 
Several observational reports have linked anthracycline 
sensitivity to HER2 positivity.5,6 HER2 ampliﬁ cation is 
linked both to multiple mechanistic pathways (proliferation, 
dediﬀ erentiation, apoptosis, DNA repair)7 and to several 
molecular events that are now viewed separately from 
HER2 ampliﬁ cation, such as TOP2A alterations and 
chromosome 17 (Ch17) centromeric duplication.8,9 Ch17 
centromeric duplication indicates duplication of the Ch17 
centromere enumeration probe (Ch17CEP)8,9 and is not 
necessarily an indicator of chromosomal duplication. Data 
suggest polysomy—deﬁ ned by duplication of the CEP—in 
fact represents duplication of subchromosomal regions, 
including the CEP, rather than whole chromosome 
duplication.10 For this report, the term Ch17CEP duplication 
represents increased CEP17 copies and should be 
interpreted in view of these emerging data.
HER2 might be the central focus or driver for a region 
of genomic instability centred around 17q12, frequently 
being associated with ampliﬁ cation or deletion of other 
genes within this region including GRB7, RARA (retinoic 
acid receptor), THRA1, CDC6, and TOP2A. HER2 
ampliﬁ cation is also closely associated with Ch17CEP 
duplication.9 Ch17 is the second most gene-dense 
chromosome in the human genome, housing several 
genes with key roles in breast cancer (BRCA1, HER2) 
and DNA repair (TP53, RAD51C, RAD52B).11 However, 
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Ch17CEP duplication has not been mechanistically linked 
to these pathways, which makes the key molecular 
change associated with clinical beneﬁ t from anthracycline-
based chemotherapy diﬃ  cult to identify. 
Research so far has focused almost exclusively on 
HER2 and TOP2A, both of which have been linked to 
anthracycline sensitivity.6,12 Nevertheless, genes such as 
BRCA1, RAD51C, and TP53, all with a role in DNA repair, 
might also modify response to chemotherapy. However, 
Ch17CEP duplication9,13 is also a potential marker of 
genomic instability in breast cancer and thus sensitivity 
to chemotherapy. 
The UK National Epirubicin Adjuvant Trial 
(NEAT/BR9601) trials examined the addition of the 
anthra cycline epirubicin to cyclophosphamide, metho-
trexate, and ﬂ uorouracil (CMF). These trials were 
designed in parallel, with a prospectively preplanned 
joint analysis of the primary endpoints,14 and together 
provide samples for an adequately powered biomarker 
analysis. We planned prospectively to investigate markers 
predictive of anthracycline beneﬁ t, including type I 
receptor tyrosine kinase (RTK) signalling pathways 
(epidermal growth factor receptor [EGFR], HER1, HER2, 
HER3), Ki67, TOP2A alterations, and Ch17CEP 
duplication. Data for HER1–3, Ki67, and TOP2A in the 
BR9601 study were reported previously.12
Methods
Study design and patients
NEAT and BR9601 recruited 2391 pre-menopausal and 
post-menopausal women with completely excised, 
histologically conﬁ rmed breast cancer with a clear 
indication for adjuvant chemotherapy.14 The 2021 patients 
in NEAT were randomly assigned, in a 1:1 randomisation, 
to receive either epirubicin (100 mg/m² intravenously 
every 3 weeks) for four cycles followed by CMF 
(cyclophosphamide 100 mg/m² orally days 1–14 or 
cyclophosphamide 600 mg/m² days 1 and 8, intravenously; 
methotrexate 40 mg/m² days 1 and 8; ﬂ uorouracil 
600 mg/m² days 1 and 8 every 4 weeks) for four cycles or 
to receive CMF for six cycles. The 370 patients in BR9601 
were randomly assigned, in a 1:1 randomisation, to 
receive either epirubicin (100 mg/m² every 3 weeks) for 
four cycles followed by CMF (cyclophosphamide 
750 mg/m², methotrexate 50 mg/m², and ﬂ uorouracil 
600 mg/m² every 3 weeks given intravenously) for four 
cycles or to receive CMF for eight cycles.14 Both protocols 
were approved by central and local ethics committees, 
and patients provided written informed consent before 
randomisation. There was a prospectively preplanned 
agreement for a joint analysis with the primary outcomes 
of relapse-free and overall survival.14
For the present study, routine pathology tissue blocks 
were retrieved from the NEAT/BR9601 trials and tissue 
microarrays constructed according to current guidelines 
for breast tissue collections.15 Blocks were retrieved and 
tissue microarrays constructed from 80% of NEAT 
samples (1623/2021) and from 86% of BR9601 samples 
(318/370) for this study. 
Triple-colour ﬂ uorescent in-situ hybridisation (FISH) 
and immunohistochemistry
FISH was done with a triple-colour probe for HER2, 
TOP2A, and Ch17 (Abbot Vysis, Maidenhead, UK) as 
described previously.12 HER2 ampliﬁ cation was deﬁ ned 
as a ratio of HER2 to Ch17CEP of 2·0 or greater, TOP2A 
ampliﬁ cation as a ratio of TOP2A to Ch17CEP of more 
than 1·5, and TOP2A deletion as a ratio of TOP2A to 
Ch17CEP of less than 0·8. Oestrogen-receptor and 
progesterone-receptor status and grade, determined at 
local laboratories, were recorded, and immuno histo-
chemistry done centrally for HER2, EGFR, HER3, and 
Ki67 as previously described.12 All results were analysed 
by one observer (AM), who was masked to clinical data 
and who had extensive experience in FISH and immuno-
histochemistry analysis; 10% of cases were dual scored 
and a high degree of interobserved agreement 
Number of 
patients (%)
HR (95% CI); p value
Relapse-free survival Overall survival
HER2
HER2 normal 1395 (79·2) 1·00 1·00
HER2 ampliﬁ cation 367 (20·8) 1·59 (1·32–1·92); p<0·0001 1·79 (1·47–2·19); p<0·0001
TOP2A
TOP2A normal 1593 (90·4) 1·00 1·00
TOP2A ampliﬁ cation 169 (9·6) 0·77 (0·57–1·05); p=0·09 0·88 (0·64–1·20); p=0·41
TOP2A
TOP2A normal 1571 (89·2) 1·00 1·00
TOP2A deletion 191 (10·8) 1·52 (1·20–1·92); p=0·0006 1·62 (1·26–2·08); p=0·0002
Ch17CEP
Ch17CEP normal 1356 (77·0) 1·00 1·00
Ch17CEP duplication 406 (23·0) 1·12 (0·93–1·36); p=0·24 1·17 (0·95–1·44); p=0·13
Ki67
Ki67 low 736 (39·3) 1·00 1·00
Ki67 high 1136 (60·7) 1·12 (0·95–1·32); p=0·19 1·11 (0·93–1·33); p=0·26
EGFR
EGFR negative 1473 (77·1) 1·00 1·00
EGFR positive 437 (22·9) 1·20 (1·01–1·44); p=0·04 1·25 (1·02–1·52); p=0·03
HER2 IHC
HER2 IHC negative 1516 (79·5) 1·00 1·00
HER2 IHC positive 391 (20·5) 1·59 (1·32–1·90); p<0·0001 1·77 (1·46–2·15); p<0·0001
HER3 IHC
HER3 IHC negative 1353 (71·3) 1·00 1·00
HER3 IHC positive 544 (28·7) 0·98 (0·82–1·17); p=0·84 0·94 (0·76–1·15); p=0·55
HER1–3
HER1–3 negative 753 (43·5) 1·00 1·00
HER1–3 positive 979 (56·5) 1·35 (1·13–1·60); p=0·0007 1·35 (1·12–1·63); p=0·002
Missing values are not shown. HR=hazard ratio. Ch17CEP=chromosome 17 centromere enumeration probe. 
EGFR=epidermal growth factor receptor. IHC=immunohistochemistry. 
Table 1: Biomarker analysis and relation with overall and relapse-free survival
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documented as previously described.16,17 Ch17 copy 
number was assessed by counting all cells with a 
minimum of one Ch17 signal per cell, and Ch17CEP 
duplication deﬁ ned as greater than 1·86 observed CEP 
signals per cell.9
Statistical analysis
The 1941 eligible samples from this trial population 
would be adequate to identify, with at least 80% power, 
prognostic hazard ratios (HRs) of 1·5 and treatment by 
marker interactions of 2·0, with the exception of TOP2A, 
for which the values would be 1·6 and 2·3, respectively, 
owing to the lower frequency of TOP2A aberrations in 
this patient population.18 SAS (version 9.1) was used for 
statistical analysis. Pearson’s χ² test was used to measure 
associations between markers. Kaplan-Meier and 
log-rank analysis were used to compare relapse-free 
and overall survival as described previously.19 HRs and 
their CIs were calculated from log-rank statistics. Cox’s 
proportional hazards models were used to explore 
treatment by marker interactions. All reported p values 
are two-sided. Graphical examination showed no clear 
departure from proportional hazards.
The analysis plan—to assess the interaction of 
type I RTKs (HER1–3), Ki67, TOP2A, and Ch17CEP—was 
prospectively planned, before any statistical analysis and 
merging of biomarker and clinical data. In accordance 
with the statistical analysis plan, HER2, TOP2A, Ch17CEP 
Events/patients
ECMF CMF
HR (CI; ECMF:CMF)
0 0·5 1·0
ECMF better CMF better
1·5 2·0
HER2 ampliﬁcation 74/193 (38·3%) 78/174 (44·8%) 0·77 (0·50–1·17)
HER2 normal 189/690 (27·4%) 229/705 (32·5%) 0·79 (0·62–1·02)
Total 263/883 (29·8%) 307/879 (34·9%) 0·79 (0·67–0·93; p=0·004)
Interaction between two groups χ21=0·0; p=0·85
TOP2A ampliﬁcation 24/91 (26·4%) 21/78 (26·9%) 0·92 (0·43–2·00)
TOP2A normal 239/792 (30·2%) 286/801 (35·7%) 0·79 (0·63–0·99)
Total 263/883 (29·8%) 307/879 (34·9%) 0·80 (0·68–0·94; p=0·008)
Interaction between two groups χ21=0·2; p=0·62
TOP2A deletion 34/93 (36·6%) 46/98 (46·9%) 0·70 (0·39–1·24)
TOP2A normal 229/790 (29·0%) 261/781 (33·4%) 0·82 (0·65–1·03)
Total 263/883 (29·8%) 307/879 (34·9%) 0·80 (0·68–0·94; p=0·008)
Interaction between two groups χ21=0·4; p=0·51
Ch17CEP duplication 47/191 (24·6%) 92/215 (42·8%) 0·52 (0·34–0·81)
Ch17CEP normal 216/692 (31·2%) 215/664 (32·4%) 0·92 (0·72–1·18)
Total 263/883 (29·8%) 307/879 (34·9%) 0·80 (0·68–0·95; p=0·009)
Interaction between two groups χ21=8·4; p=0·004
Ki67 high 173/571 (30·3%) 206/565 (36·5%) 0·78 (0·59–1·01)
Ki67 low 102/361 (28·3%) 129/375 (34·4%) 0·77 (0·55–1·08)
Total 275/932 (29·5%) 335/940 (35·6%) 0·77 (0·66–0·90; p=0·001)
Interaction between two groups χ21=0·0; p=0·95
HER2 IHC positive 75/198 (37·9%) 86/193 (44·6%) 0·78 (0·52–1·16)
HER2 IHC negative 204/746 (27·3%) 254/770 (33·0%) 0·78 (0·61–0·99)
Total 279/944 (29·6%) 340/963 (35·3%) 0·78 (0·66–0·91; p=0·002)
Interaction between two groups χ21=0·0; p=0·97
HER1–3 positive 163/485 (33·6%) 183/494 (37·0%) 0·85 (0·65–1·12)
HER1–3 negative 92/379 (24·3%) 120/374 (32·1%) 0·71 (0·50–1·01)
Total 255/864 (29·5%) 303/868 (34·9%) 0·79 (0·67–0·94; p=0·006)
Interaction between two groups χ21=1·1; p=0·29
All study 283/962 (29·4%) 347/979 (35·4%) 0·78 (0·67–0·91)
99% CI 95% CI
Figure 1: Hazard ratio (HR) plot for treatment-by-marker interactions for relapse-free survival
Ch17CEP=chromosome 17 centromere enumeration probe. IHC=immunohistochemistry. ECMF=epirubicin, cyclophosphamide, methotrexate, ﬂ uorouracil. 
CMF=cyclophosphamide, methotrexate, ﬂ uorouracil. 
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duplication, Ki67, and HER1–3 were considered in 
univariate analyses, together with conventional prognostic 
factors (age, nodal status, oestrogen-receptor status, 
grade, and tumour size). HER2, TOP2A, and Ch17CEP 
as individual markers were entered in a ﬁ nal Cox model 
together with the treatment term and each of the three 
treatment-by-marker interactions, with adjustment for 
conventional prognostic factors (age, nodal status, 
oestrogen-receptor status, grade, and tumour size). 
The study conformed to the REMARK guidelines.19
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The population included in this tissue microarray study 
was representative of patient and tumour characteristics 
within the main trial (webappendix p 1). Of the 
1941 patients included in this analysis, 630 (32%) relapsed 
and 516 (27%) died during follow-up (median 7·4 years, 
IQR 6·3–8·6); data from one patient were lost. The 
advantage of epirubicin and CMF compared with CMF 
with respect to relapse-free survival (HR 0·78, 95% CI 
0·66–0·91; p=0·0002) and overall survival (0·81, 
Deaths/patients
ECMF CMF
HR (CI; ECMF:CMF)
0 0·5 1·0
ECMF better CMF better
1·5 2·0
HER2 ampliﬁcation 66/193 (34·2%) 72/174 (41·4%) 0·74 (0·48–1·16)
HER2 normal 158/690 (22·9%) 183/705 (26·0%) 0·84 (0·64–1·11)
Total 224/883 (25·4%) 255/879 (29·0%) 0·81 (0·68–0·97; p=0·02)
Interaction between two groups χ21=0·4; p=0·55
TOP2A ampliﬁcation 22/91 (24·2%) 20/78 (25·6%) 0·87 (0·39–1·94)
TOP2A normal 202/792 (25·5%) 235/801 (29·3%) 0·83 (0·65–1·06)
Total 224/883 (25·4%) 255/879 (29·0%) 0·83 (0·69–0·99; p=0·04)
Interaction between two groups χ21=0·0; p=0·88
TOP2A deletion 31/93 (33·3%) 40/98 (40·8%) 0·74 (0·40–1·37)
TOP2A normal 193/790 (24·4%) 215/781 (27·5%) 0·85 (0·66–1·09)
Total 224/883 (25·4%) 255/879 (29·0%) 0·83 (0·69–0·99; p=0·04)
Interaction between two groups χ21=0·3; p=0·61
Ch17CEP duplication 43/191 (22·5%) 78/215 (36·3%) 0·57 (0·36–0·92)
Ch17CEP normal 181/692 (26·2%) 177/664 (26·7%) 0·94 (0·72–1·24)
Total 224/883 (25·4%) 255/879 (29·0%) 0·83 (0·69–0·99; p=0·04)
Interaction between two groups χ21=5·6; p=0·02
Ki67 high 141/571 (24·7%) 169/565 (29·9%) 0·78 (0·58–1·05)
Ki67 low 87/361 (24·1%) 104/375 (27·7%) 0·82 (0·56–1·19)
Total 228/932 (24·5%) 273/940 (29·0%) 0·80 (0·67–0·95; p=0·01)
Interaction between two groups χ21=0·1; p=0·80
HER2 IHC positive 65/198 (32·8%) 78/193 (40·4%) 0·75 (0·49–1·16)
HER2 IHC negative 167/746 (22·4%) 199/770 (25·8%) 0·83 (0·63–1·08)
Total 232/944 (24·6%) 277/963 (28·8%) 0·80 (0·68–0·96; p=0·01)
Interaction between two groups χ21=0·2; p=0·64
HER1–3 positive 139/485 (28·7%) 153/494 (31·0%) 0·88 (0·65–1·19)
HER1–3 negative 78/379 (20·6%) 99/374 (26·5%) 0·73 (0·50–1·08)
Total 217/864 (25·1%) 252/868 (29·0%) 0·82 (0·68–0·98; p=0·03)
Interaction between two groups χ21=0·9; p=0·34
All study 235/962 (24·4%) 281/979 (28·7%) 0·81 (0·68–0·96)
99% CI 95% CI
Figure 2: Hazard ratio (HR) plot for treatment-by-marker interactions for overall survival
Ch17CEP=chromosome 17 centromere enumeration probe. IHC=immunohistochemistry. ECMF=epirubicin, cyclophosphamide, methotrexate, ﬂ uorouracil. 
CMF=cyclophosphamide, methotrexate, ﬂ uorouracil. 
See Online for webappendix
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0·68–0·96; p=0·02) was very similar to that in the overall 
population.14 All subsequent analyses were restricted to 
these cases, or subsets thereof.
Results for HER2, TOP2A, and Ch17 were available for 
1762 (91%) available cases (table 1). Of the eligible cases, 
367 of 1762 (21%) were HER2 ampliﬁ ed, and Ch17CEP 
duplication was recorded in 406 (23%).
The prognostic eﬀ ect of each biological marker assessed 
in this study was ﬁ rst tested with respect to relapse-free 
and overall survival in all 1762 patients, irrespective of their 
allocated adjuvant chemotherapy. In univariate analysis, 
HER2 ampliﬁ cation, TOP2A deletion, and HER1–3 and 
EGFR expression were signiﬁ cantly associated with a 
worse outcome for both relapse-free and overall survival 
(table 1), although the eﬀ ect observed with EGFR expression 
was of borderline signiﬁ cance. We noted no such relation 
with TOP2A ampliﬁ cation, Ch17CEP duplication, or Ki67 
expression (table 1).
Subsequent analyses focused on possible diﬀ erential 
eﬀ ects of markers on relapse-free and overall survival 
between patients receiving anthracycline treatment 
(epirubicin and CMF) and those given CMF alone. 
Figures 1 and 2 show HR estimates for relapse-free and 
overall survival by treatment and molecular biomarker 
subgroup, with biomarkers dichotomised as positive/high 
or negative/low. We detected no signiﬁ cant interactions 
between treatment with epirubicin and biomarker for 
HER2, HER1–3, TOP2A (ampliﬁ cation, deletion, or 
combined), or Ki67 for either relapse-free or overall 
survival in uncorrected treatment by marker analyses.
Ch17CEP duplication was associated with increased 
beneﬁ t from epirubicin plus CMF compared with CMF 
(ﬁ gures 1–3) for both relapse-free and overall survival 
(univariate treatment by marker interactions p=0·004 
and p=0·02, respectively). For tumours with normal 
Ch17CEP copy number, very little or no beneﬁ t was 
derived from the addition of the anthracycline (relapse-
free survival HR 0·92, 95% CI 0·76–1·11, ﬁ gure 3A; 
overall survival 0·94, 0·77–1·16, ﬁ gure 3C). Conversely, 
for patients with tumours exhibiting Ch17CEP 
duplication, the relative risk of relapse and death was 
substantially lower for those receiving epirubicin and 
CMF than CMF (relapse-free survival 0·51, 95% CI 0·36–
0·73, ﬁ gure 3B; overall survival 0·56, 0·39–0·82, 
ﬁ gure 3D). 
A single Cox regression model was done to test the 
eﬀ ects of anthracyclines, HER2 ampliﬁ cation, TOP2A 
alteration, and Ch17CEP duplication (including inter-
actions with treatment for each marker) simultaneously 
after adjustment for age, nodal status, oestrogen-receptor 
status, grade, and tumour size (table 2). The interaction 
for Ch17CEP duplication and epirubicin therapy 
remained signiﬁ cant for both relapse-free and overall 
survival (table 2).
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Figure 3: Relapse-free and overall survival for patients with tumours exhibiting Ch17CEP duplication and Ch17CEP normal
(A) Relapse-free survival for ChCEP17 normal. (B) Relapse-free survival for ChCEP17 duplication. (C) Overall survival for ChCEP17 normal. (D) Overall survival for 
ChCEP17 duplication. Ch17CEP=chromosome 17 centromere enumeration probe. ECMF=epirubicin, cyclophosphamide, methotrexate, ﬂ uorouracil. 
CMF=cyclophosphamide, methotrexate, ﬂ uorouracil.
Articles
www.thelancet.com/oncology   Vol 11   March 2010 271
Both HER2 ampliﬁ cations and TOP2A alterations 
(ampliﬁ cations or deletions) measured by FISH were 
signiﬁ cantly associated with Ch17CEP duplication 
(p<0·0001). HER2-ampliﬁ ed tumours were twice as likely 
to exhibit Ch17CEP duplication as were those that were 
not ampliﬁ ed (37% [136/367] vs 19% [270/1395], p<0·0001). 
TOP2A ampliﬁ ed or deleted tumours were also 
signiﬁ cantly more likely to exhibit Ch17CEP duplication 
than were those that were not TOP2A altered (31% [52/169] 
vs 22% [354/1593] and 65% [124/191] vs 18% [282/1571], 
respectively, webappendix p 2). An exploratory subgroup 
analysis (ﬁ gure 4) linked beneﬁ t from anthracyclines to 
Ch17CEP duplication irrespective of HER2 ampliﬁ cation 
or TOP2A alterations. The HRs for relapse-free survival in 
patients with tumours exhibiting Ch17CEP duplication 
were 0·65 (95% CI 0·32–1·29) with HER2 ampliﬁ cation 
and 0·46 (0·26–0·80) without; similarly the HRs were 
0·62 (0·33–1·16) with TOP2A alterations and 0·46 (0·25–
0·84) without. By contrast, in patients whose tumours did 
not show Ch17CEP duplication, HRs for relapse-free 
survival were 0·85 (0·50–1·45) with HER2 ampliﬁ cation 
and 0.91 (0·69–1·21) without; and 1·01 (0·51–2·01) with 
TOP2A alteration and 0·91 (0·70–1·19) without. This 
exploratory subgroup analysis (ﬁ gure 4) linked beneﬁ t 
from anthracyclines to Ch17CEP duplication irrespective 
of HER2 ampliﬁ cation or TOP2A alterations.
Discussion
In a prospectively planned and adequately powered 
analysis of biomarkers of anthracycline beneﬁ t within 
the NEAT/BR9601 clinical trials, Ch17CEP duplication, 
but not HER2 or TOP2A, was identiﬁ ed as a predictive 
biomarker of anthracycline beneﬁ t in early breast 
cancer. A signiﬁ cant treatment-by-marker interaction 
was recorded for both relapse-free and overall survival 
in multivariate analyses corrected for conventional 
pathological factors and also for treatment-by-marker 
interactions for HER2 and TOP2A. A signiﬁ cant 
reduction in the risk of both relapse and death after 
treatment with anthracycline-containing chemotherapy 
regimens was noted in patients whose tumours showed 
evidence of Ch17CEP duplication. We also noted a 
signiﬁ cant treatment-by-marker interaction between 
treatment with anthracycline-containing polychemo-
therapy and Ch17CEP duplication.
Previous evidence from smaller, underpowered, 
analyses suggested Ki67 (proliferation), HER1–3 
expression, TOP2A, and HER2 as potential biomarkers 
of anthracycline beneﬁ t;2,6,12,20–23 however, these markers 
provided no signiﬁ cant predictive value in the present 
study. HER2 ampliﬁ cation was an important prognostic 
marker in both treatment groups. Validation in a large 
meta-analysis is planned to conﬁ rm this eﬀ ect and to 
lend support to adoption of this biomarker in routine 
clinical practice.
To the best of our knowledge, the data presented here 
represent the ﬁ rst time that one can clearly deﬁ ne a 
subgroup of patients—those with Ch17CEP duplication—
for whom adjuvant anthracyclines provide signiﬁ cant 
additional treatment beneﬁ t, while identifying a larger 
group for whom alternative, non-anthracycline-
containing regimens should be considered. These data 
remain of value at a time when trastuzumab is frequently 
used to treat patients with HER2-positive breast cancer, 
since about two-thirds of patients whose tumours have 
Ch17CEP duplication do not exhibit HER2 ampliﬁ cation. 
On the basis of the current evidence, these patients would 
still beneﬁ t from the addition of an anthracycline. 
The combined translational analysis of tumour samples 
from the UK NEAT and BR9601 studies represents, to 
our knowledge, the largest single study so far that has 
simultaneously assessed the predictive value of HER2 
ampliﬁ cation, and alterations in TOP2A and other 
markers, for beneﬁ t from anthracycline therapy. The 
HR (95% CI) p value
Relapse-free survival
Age ≤50 years 1·12 (0·94–1·33) 0·22
Breast conserving surgery 0·83 (0·69–0·99) 0·04
Node involvement 1·83 (1·61–2·07) <0·0001
Oestrogen-receptor negative 0·93 (0·73–1·18) 0·53
Oestrogen-receptor positive 0·75 (0·60–0·94) 0·01
Tumour grade 1·29 (1·10–1·52) 0·002
Tumour diameter 1·01 (1·00–1·01) 0·002
ECMF 0·89 (0·72–1·10) 0·27
HER2 ampliﬁ cation 1·61 (1·17–2·21) 0·003
TOP2A alteration 1·40 (0·99–2·00) 0·06
Ch17CEP duplication 1·43 (1·09–1·87) 0·01
HER2*ECMF interaction 1·03 (0·66–1·61) 0·89
TOP2A*ECMF interaction 0·90 (0·55–1·49) 0·69
Ch17CEP*ECMF interaction 0·54 (0·35–0·83) 0·005
Overall survival
Age ≤50 years 0·98 (0·81–1·19) 0·86
Breast conserving surgery 0·82 (0·67–1·00) 0·05
Node involvement 1·73 (1·51–1·98) <0·0001
Oestrogen-receptor negative 0·88 (0·69–1·14) 0·34
Oestrogen-receptor positive 0·66 (0·52–0·84) 0·0008
Tumour grade 1·34 (1·11–1·60) 0·002
Tumour diameter 1·01 (1·00–1·01) 0·005
ECMF 0·92 (0·72–1·16) 0·47
HER2 ampliﬁ cation 1·84 (1·31–2·58) 0·0005
TOP2A alteration 1·36 (0·93–2·00) 0·12
Ch17CEP duplication 1·37 (1·01–1·84) 0·04
HER2*ECMF interaction 0·91 (0·56–1·47) 0·70
TOP2A*ECMF interaction 0·85 (0·50–1·45) 0·54
Ch17CEP*ECMF interaction 0·60 (0·38–0·95) 0·03
Adjusted for age group, surgery group, nodal group, oestrogen-receptor status, 
grade, and tumour size. HR=hazard ratio. ECMF=epirubicin, cyclophosphamide, 
methotrexate, ﬂ uorouracil. Ch17CEP=chromosome 17 centromere enumeration 
probe.
Table 2: Eﬀ ect of HER2, TOP2A, and Ch17CEP on relapse-free and overall 
survival, adjusted by patient and tumour characteristics
Articles
272 www.thelancet.com/oncology   Vol 11   March 2010
combination of these trials reported here was prospectively 
shown to be adequately powered to detect clinically 
relevant treatment-by-marker interactions. 
A preliminary report of data from the NCIC MA5 
study24 also reported Ch17CEP duplication to be associated 
with increased disease-free survival in patients given an 
anthracycline. By contrast with ﬁ ndings reported here, 
MA5 indicated that beneﬁ t from anthracyclines was 
associated with HER2 and TOP2A ampliﬁ cation.25,26 The 
reduction in risk of relapse was much the same for 
patients in both NEAT/BR9601 and MA5 whose tumours 
exhibited Ch17CEP duplication when given an anthra-
cycline rather than CMF alone; no beneﬁ t was recorded 
in patients with tumours with normal Ch17CEP.24 
No signiﬁ cant treatment-by-marker interaction for 
either HER2 or TOP2A was detected in the multivariate 
regression analysis, although HER2 gene ampliﬁ cation 
was, as expected, prognostic for both overall and 
relapse-free survival in both treatment groups. This 
ﬁ nding strongly suggests that neither gene is of clinical 
signiﬁ cance in terms of predicting clinical beneﬁ t from 
adjuvant anthracyclines, and reaﬃ  rms the strong 
prognostic eﬀ ect of HER2 ampliﬁ cation. Previous data 
from other groups22,25–28 are, however, conﬂ icting, with 
some studies suggesting HER2 and others HER2 and 
TOP2A as potential predictive markers for anthracycline 
beneﬁ t. These results also contrast with the recent 
pooled analysis by Gennari and colleagues,29 which did 
not include data for TOP2A and Ch17CEP. Preliminary 
results of a meta-analysis30 using individual patient data 
in 1944 cases from four clinical trials,12,22,26,27 including 
295 of the BR9601 trial patients reported here, also 
showed no signiﬁ cant predictive eﬀ ect with HER2, and 
only a marginally signiﬁ cant eﬀ ect for TOP2A for 
disease-free but not overall survival. We believe that 
many previous smaller studies lacked the power to 
robustly test interactions, and that neither HER2 
ampliﬁ cation nor TOP2A gene alterations can be 
regarded as predictive for response to anthracyclines. A 
review of previously published studies (webappendix p 3) 
accords with these conﬂ icting results.22,25–28,31–33 Only the 
MA5 trial shows a signiﬁ cant interaction with HER2; 
an early study by Paik and colleagues32 of similar size to 
our study, but using only immunohistochemistry, also 
did not show a signiﬁ cant interaction between HER2 
and anthracyclines. Our study is both adequately 
powered and includes comprehensive analysis of 
previous candidate biomarkers of anthracycline beneﬁ t. 
Ki67 was not associated with beneﬁ t from anthracyclines, 
a result that does not contradict previous results, 
suggesting highly proliferative tumours beneﬁ t 
preferentially from chemotherapy.
Of note, HER2 and TOP2A ampliﬁ cation and TOP2A 
deletion were signiﬁ cantly associated with Ch17CEP 
duplication, but the beneﬁ t from the anthracycline 
seemed to be restricted to patients whose tumours 
exhibited Ch17CEP duplication (ﬁ gure 4). A signiﬁ cant 
proportion of these tumours were not HER2 ampliﬁ ed, 
suggesting a role for anthracyclines in patients with 
HER2-negative breast tumours. Patients whose tumours 
were either HER2 ampliﬁ ed or TOP2A ampliﬁ ed or 
deleted, but were normal for Ch17CEP, gained no 
apparent beneﬁ t from addition of the anthracycline 
(ﬁ gure 4). This ﬁ nding suggests that in previous studies, 
TOP2A and HER2 might have acted as incomplete 
surrogate markers of Ch17CEP duplication. This result 
also suggests that in our own previous report,12 on 
HER1–3 expression in the BR9601 subgroup within the 
current trial, the small sample size masked the eﬀ ect 
reported here. The high frequency of Ch17CEP 
Deaths/patients
ECMF CMF
HR (CI; ECMF:CMF)
0 0·5 1·0
ECMF better CMF better
1·5 2·0
Ch17CEP normal, HER2 normal 164/564 (29·1%) 171/561 (30·5%) 0·91 (0·69–1·21)
Ch17CEP normal, HER2 ampliﬁcation 52/128 (40·6%) 44/103 (42·7%) 0·85 (0·50–1·45)
Ch17CEP duplication, HER2 normal 25/126 (19·8%) 58/144 (40·3%) 0·46 (0·26–0·80)
Ch17CEP duplication, HER2 ampliﬁcation 22/65 (33·8%) 34/71 (47·9%) 0·65 (0·32–1·29)
Heterogeneity between four groups χ23=8·7; p=0·03
Ch17CEP normal, TOP2A normal 183/590 (31·0%) 190/582 (32·6%) 0·91 (0·70–1·19)
Ch17CEP normal, TOP2A alteration 33/102 (32·4%) 25/82 (30·5%) 1·01 (0·51–2·01)
Ch17CEP duplication, TOP2A normal 22/109 (20·2%) 50/121 (41·3%) 0·46 (0·25–0·84)
Ch17CEP duplication, TOP2A alteration 25/82 (30·5%) 42/94 (44·7%) 0·62 (0·33–1·16)
Heterogeneity between four groups χ23=9·1; p=0·03
All study 283/962 (29·4%) 347/979 (35·4%) 0·78 (0·67–0·91)
99% CI 95% CI
Figure 4: Hazard ratio (HR) plot for treatment by marker interactions for relapse-free survival stratiﬁ ed by Ch17CEP and HER2/TOP2A 
Ch17CEP=chromosome 17 centromere enumeration probe. ECMF=epirubicin, cyclophosphamide, methotrexate, ﬂ uorouracil. CMF=cyclophosphamide, 
methotrexate, ﬂ uorouracil.
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duplication in TOP2A deleted cases in particular could 
explain the previously paradoxical result that these 
patients beneﬁ t from anthracyclines when other data 
suggest that TOP2A deleted cell lines are anthracycline 
resistant.22,34 The results of the BCIRG006 study6 suggest 
that in a population, all of whom have tumours that are 
HER2 ampliﬁ ed, there might be an additional eﬀ ect of 
TOP2A ampliﬁ cation, although the role of Ch17CEP 
duplication has not been explored in BCIRG006 so far. 
Our present data do not rule out such an additional 
eﬀ ect of TOP2A in HER2-positive cancers since our 
study was done in a mixed HER2 population, and might 
be underpowered to detect any additional eﬀ ect of 
TOP2A above that seen for Ch17CEP in the HER2-
ampliﬁ ed subgroup. Crucially, our data clearly lend 
support to a continuing role for anthracycline treatment 
in a proportion of HER2-negative breast cancers. 
Combined analysis of these separate markers in this 
study further underscores the potential predictive value 
of Ch17CEP duplication over and above both HER2 and 
TOP2A. 
A mechanistic connection between Ch17CEP 
duplication and anthracycline beneﬁ t is not immediately 
obvious. We deﬁ ned Ch17CEP duplication as an increase 
in the relative mean copy number of the CEP, which 
hybridises to the pericentromeric α-satellite repeat on 
Ch17, above that observed in non-tumour breast tissues.9 
Although there are several diﬀ erent approaches used to 
identify CEP17 duplication, only two have been validated 
against observations in non-neoplastic breast samples.9,35 
The diﬀ erent cutoﬀ s in these studies relate solely to 
diﬀ erent counting assumptions (Watters and colleagues9 
count all cells with at least one Ch17CEP signal; Wang 
and colleagues35 count cells with at least two Ch17CEP 
signals), but in all other aspects they are identical. Other 
less robustly validated cutoﬀ s select only a subset of cases 
with Ch17CEP duplications (JMSB, unpublished 
observations). The eﬀ ect that we recorded might be an 
indicator of changes, including imbalanced trans-
locations, subchromosomal ampliﬁ cation or deletion, or 
whole chromosome or genome duplication. Most 
previous studies using FISH interpreted duplication of 
Ch17CEP as chromosomal polysomy. The CEP marker 
does not, however, identify polysomy; therefore, we have 
used the more accurate description of Ch17CEP 
duplication to describe this ﬁ nding. Our approach does 
not invalidate previous deﬁ nitions of HER2 ampliﬁ cation 
since these deﬁ nitions were also based on the ratio of the 
HER2 gene and the Ch17 centromere, irrespective of the 
underlying chromosomal defect present. Our deﬁ nition 
of HER2 ampliﬁ cation still identiﬁ es patients with poor 
prognosis, HER2 protein overexpression, and potential 
for response to trastuzumab.
The observation that Ch17CEP duplication is associated 
with beneﬁ t from anthracyclines could oﬀ er a pragmatic 
approach to selection of patients for such therapy. It 
provides, however, little insight into potential mech-
anisms of action. Recent reports suggest that Ch17 
polysomy is far less common in early breast cancer than 
was previously suggested, and that Ch17CEP duplication 
does not simply indicate polysomy or tumour aneuploidy 
but also identiﬁ es cancers with subchromosomal 
duplication or ampliﬁ cation of the Ch17CEP region 
(which is close to the HER2 amplicon).10,36 At present we 
cannot distinguish which of these diﬀ erent chromo-
somal abnormalities might be associated with the 
underlying mech anism of anthracycline sensitivity. 
Further research, perhaps with comparative genomic 
hybridisation or expression array analysis, will be needed 
to elucidate potential mechanisms underlying the 
current observation. The many mechanistic explanations 
for the observations reported here should be explored 
before we can suggest strategies to improve the future 
potential of DNA-damaging agents in populations who 
are resistant to anthracyclines.
In conclusion, in this large, adequately powered, 
clinical trial population (NEAT/BR9601), Ch17CEP 
duplication, but not HER2 or TOP2A, was identiﬁ ed as a 
biomarker of anthracycline beneﬁ t in patients with early 
breast cancer. Validation in a larger meta-analysis is 
needed to provide conﬁ rmatory evidence to support the 
adoption of this biomarker in routine clinical practice.
Contributors
JMSB was responsible for translational study design, coordination, data 
collection, statistical analysis plan, management of biological data, and 
the writing of the report. AFM was responsible for collection of tissue 
from BR9601, tissue microarray construction, doing the molecular 
analyses and scoring of samples, and coordinating the data collection; 
and contributed to the writing of the report. JAD was responsible for the 
statistical analysis plan, doing statistical analysis, and the writing of the 
report. CMcC was responsible for doing the statistical analysis and the 
writing of the report. SJ was responsible for tissue collection in the 
NEAT study. CJT and DAC were responsible for the collection and 
analysis of the BR9601 clinical data and study design, and contributed to 
the writing of the report. JT provided pathological support and quality 
assurance of results and contributed to manuscript report. FMC was 
responsible for collection of tissue from BR9601 and NEAT, tissue 
microarray construction, and quality control of assay results. DWR was 
responsible for the collection and analysis of the NEAT clinical data. 
EP, HE, PP, and CC were responsible for setting up pathological review 
of all the tumour samples from the NEAT trial, guiding tissue 
microarray construction, and development and maintenance of the 
associated translational research databases. LH was responsible for 
preparing the data from the NEAT/BR9601 trials. HE was responsible for 
the collection and analysis of the NEAT clinical data. CJP was 
responsible for the translational study design collection and analysis of 
the NEAT clinical data. All authors contributed to the ﬁ nal report. 
Conﬂ icts of interest
JMSB has received honoraria and travel support from Abbott Diagnostics 
and DAKO. All other authors declared that they have no conﬂ icts of 
interest.
Acknowledgments
The Scottish Cancer Therapy Network and Institute for Statistics and 
Disease coordinated the BR9601 trial and provided funding for tissue 
collection of BR9601 blocks; the NEAT trial was coordinated by the 
Cancer Research UK Clinical Trials Unit, Birmingham, and funded by 
Cancer Research UK and an educational grant from Pharmacia; the 
translational research was funded by Cancer Research UK, and Vysis 
provided FISH kits at reduced price. Abbott provided funding in kind via 
free or reduced price reagents.
Articles
274 www.thelancet.com/oncology   Vol 11   March 2010
References
1  Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human 
breast tumours. Nature 2000; 406: 747–52.
2  Spears M, Kenicer J, Munro AF, Bartlett JMS. Type I receptor 
tyrosine kinases as predictive or prognostic markers in early breast 
cancer. Biomarker Med 2008; 2: 397–407.
3  Tovey SM, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JMS. 
Can molecular markers predict when to implement treatment with 
aromatase inhibitors in invasive breast cancer? 
Clin Cancer Res 2005; 11: 4835–42.
4  Bartlett JMS, Ellis IO, Dowsett M, et al. Human epidermal growth 
factor receptor 2 status correlates with lymph node involvement in 
patients with estrogen receptor (ER) negative, but with grade in 
those with ER-positive early-stage breast cancer suitable for 
cytotoxic chemotherapy. J Clin Oncol 2007; 25: 4423–30.
5  Miyoshi Y, Kurosumi M, Kurebayashi J, et al. Topoisomerase II 
alpha-positive and BRCA1-negative phenotype: association with 
favorable response to epirubicin-based regimens for human breast 
cancers. Cancer Letts 2008; 264: 44–53.
6  Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O’Malley F, 
Dhesy-Thind B. HER-2 and topoisomerase II as predictors of 
response to chemotherapy. J Clin Oncol 2008; 26: 736–44.
7  Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast 
cancer—the HER-2/neu gene and protein. Mol Cell Proteomic 2004; 
3: 379–98.
8  Jarvinen TAH, Kononen J, Peltohuikko M, Isola J. Expression of 
topoisomerase II alpha is associated with rapid cell proliferation, 
aneuploidy, and c-erbB2 overexpression in breast cancer. 
Am J Pathol 1996; 148: 2073–82.
9  Watters AD, Going JJ, Cooke TG, Bartlett JMS. Chromosome 17 
aneusomy is associated with poor prognostic factors in invasive 
breast carcinoma. Breast Cancer Res Treat 2003; 77: 109–14.
10  Yeh I-T, Martin MA, Robetorye RS, et al. Clinical validation of an 
array CGH test for HER2 status in breast cancer reveals that 
polysomy 17 is a rare event. Mod Pathol 2009; 22: 1169–75. 
11  Zody MC, Garber M, Adams DJ, et al. DNA sequence of human 
chromosome 17 and analysis of rearrangement in the human 
lineage. Nature 2006; 440: 1045–49.
12  Bartlett JMS, Munro AF, Cameron DA, Thomas JS, Prescott RJ, 
Twelves C. Type I receptor tyrosine kinase proﬁ les identify patients 
with enhanced beneﬁ t from anthracyclines in the BR9601 adjuvant 
breast cancer chemotherapy trial. J Clin Oncol 2008; 26: 5027–35. 
13  Corzo C, Bellosillo B, Corominas JM, et al. Does polysomy of 
chromosome 17 have a role in ERBB2 and topoisomerase II alpha 
expression? Tumor Biol 2007; 28: 221–28.
14  Poole CJ, Earl HM, Hiller L, et al. Epirubicin and 
cyclophosphamide, methotrexate, and ﬂ uorouracil as adjuvant 
therapy for early breast cancer. N Engl J Med 2006; 355: 1851–62.
15  Leyland-Jones BR, Ambrosone CB, Bartlett J, et al. 
Recommendations for collection and handling of specimens from 
group breast cancer clinical trials. J Clin Oncol 2008; 26: 5638–44.
16  Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in 
immunohistochemical analysis of protein expression, time for 
a change? Histopathology 2006; 48: 787–94.
17  Bartlett JMS, Going JJ, Mallon EA, et al. Evaluating HER2 
ampliﬁ cation and overexpression in breast cancer. J Pathol 2001; 
195: 422–28.
18  Schmoor C, Sauerbrei W, Schumacher M. Sample size 
considerations for the evaluation of prognostic factors in survival 
analysis. Stat Med 2000; 19: 441–52. 
19  McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, 
Clark GM. REporting recommendations for tumour MARKer 
prognostic studies (REMARK). Br J Cancer 2006; 93: 387–91. 
20  Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, 
Larsimont D. Topoisomerase II alpha as a marker predicting 
anthracyclines’ activity in early breast cancer patients: Ready for the 
primetime? Eur J Cancer 2008; 44: 2791–98.
21  Piccart-Gebhart MJ. Anthracyclines and the tailoring of treatment 
for early breast cancer. N Engl J Med 2006; 354: 2177–79.
22  Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of 
topoismerase IIa ampliﬁ cations and deletions as predictive markers 
in primary breast cancer patients randomly assigned to 
cyclophosphamide, methotrexate, and ﬂ uorouracil or 
cyclophosphamide, epirubicin and ﬂ uorouracil: Danish breast 
cancer cooperative group. J Clin Oncol 2005; 23: 7483–90. 
23  Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive 
marker in a population of advanced breast cancer patients randomly 
treated either with single-agent doxorubicin or single-agent 
docetaxel. Breast Cancer Res Treat 2004; 86: 197–206.
24  Bartlett JMS, Desmedt C, Munro A, et al. Chromosome 17 
polysomy: a unifying hypothesis underlying beneﬁ t from adjuvant 
anthracyclines? Cancer Res 2009; 69: 364S.
25  O’Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and 
responsiveness of breast cancer to adjuvant chemotherapy. 
J Natl Cancer Inst 2009; 101: 644–50.
26  Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and 
responsiveness of breast cancer to adjuvant chemotherapy. 
N Engl J Med 2006; 354: 2103–11.
27  Di Leo A, Gancberg D, Larsimont D, et al. HER-2 ampliﬁ cation and 
topoisomerase II{alpha} gene aberrations as predictive markers in 
node-positive breast cancer patients randomly treated either with an 
anthracycline-based therapy or with cyclophosphamide, 
methotrexate, and 5-ﬂ uorouracil. Clin Cancer Res 2002; 8: 1107–16.
28  Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topo-isomerase 
II alpha as predictive markers in a population of node-positive breast 
cancer patients randomly treated with adjuvant CMF or epirubicin 
plus cyclophosphamide. Ann Oncol 2001; 12: 1081–89.
29  Gennari A, Sormani MP, Pronzato P, et al. HER2 status and 
eﬃ  cacy of adjuvant anthracyclines in early breast cancer: a pooled 
analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14–20.
30  Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials 
evaluating the predictive value of HER2 and topoisomerase II alpha 
in early breast cancer patients treated with CMF or anthracycline-
based adjuvant therapy. Cancer Res 2009; 69: 99S.
31  De Laurentiis M, Caputo F, Massarelli E, et al. HER2 expression 
and anthracycline eﬀ ect: results from the Naples GUN3 
Randomized Trial. Proc Am Soc Clin Oncol 2001; 20: 133 (abstr). 
32  Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant 
chemotherapy for invasive breast cancer: National Surgical 
Adjuvant Breast and Bowel Project Protocol B-15. 
J Natl Cancer Inst 2000; 92: 1991–98.
33  Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression 
and doxorubicin in adjuvant chemotherapy for resectable breast 
cancer. J Clin Oncol 2003; 21: 458–62.
34  Jarvinen TAH, Tanner M, Rantanen V, et al. Ampliﬁ cation and 
deletion of topoisomerase II alpha associate with ErbB-2 
ampliﬁ cation and aﬀ ect sensitivity to topoisomerase II inhibitor 
doxorubicin in breast cancer. Am J Pathol 2000; 156: 839–47.
35  Wang S, Saboorian MH, Frenkel EP, et al. Aneusomy 17 in breast 
cancer: its role in HER-2/neu protein expression and implication 
for clinical assessment of HER-2/neu status. Mod Pathol 2002; 
15: 137–45.
36  Marchiò C, Lambros MB, Gugliotta P, et al. Does chromosome 17 
centromere copy number predict polysomy in breast cancer? 
A ﬂ uorescence in situ hybridization and microarray-based 
CGH analysis. J Pathol 2009; 219: 16–24. 
